Dr. Carcas on the Design and Findings of CONTROL Trial in HER2+ Breast Cancer
May 8th 2019
Lauren Carcas, MD, medical oncologist, Miami Cancer Institute, Baptist Health South Florida, discusses the design of the CONTROL trial and her personal experience with prophylaxis interventions for women with early-stage HER2-positive breast cancer receiving neratinib (Nerlynx).